中国肿瘤生物治疗杂志2025，Vol.32Issue(11)：1175-1180,6.DOI:10.3872/j.issn.1007-385x.2025.11.010
阿比特龙联合地塞米松治疗去势抵抗性前列腺癌患者的疗效及预后
Efficacy and prognosis of abiraterone combined with dexamethasone in the treatment of patients with castration-resistant prostate cancer
张建龙 1黄新化 1吴钦福 1易熠 1林超禄1
作者信息
- 1. 福建医科大学附属龙岩第一医院 泌尿外科,福建 龙岩 364000
- 折叠
摘要
Abstract
Objective:To investigate the effects of dexamethasone combined with abiraterone on the urodynamic parameters,levels of androgen receptor splice variant 7(AR-V7)and human homeobox B13(HoxB13)in peripheral blood circulating tumor cells,and survival prognosis of patients with castration-resistant prostate cancer(CRPC).Methods:Medical records of 114 CRPC patients admitted to our hospital were retrospectively selected.According to the treatment regimen,they were divided into the control group(treated with 0.5 mg dexamethasone,n=51)and the observation group(treated with 0.5 mg dexamethasone combined with 1 000 mg abiraterone,n=63).The efficacy,urodynamic parameters,levels of AR-V7 and HoxB13 in peripheral blood circulating tumor cells,and survival prognosis of the two groups were compared.Results:There were 63 patients in the observation group and 51 in the control group.After 8 weeks of treatment,both the disease control rate(42.86%vs 23.53%)and the objective response rate(96.83%vs 86.27%)were significantly higher in the observation group than in the control group(P<0.05).The maximum urinary flow rate([14.58±1.02]mL/s vs[11.18±1.16]mL/s)and the average urinary flow rate([12.92±1.21]mL/s vs([9.83±0.59]mL/s)were significantly higher in the observation group,while the residual urine volume([24.12±1.96]mL vs[28.03±1.68]mL)was significantly lower than in the control group(all P<0.05).The expression levels of AR-V7 mRNA were similar between the observation group(1.78±0.32)and the control group(1.68±0.46),with no statistically significant difference(P>0.05).However,the expression level of HoxB13 mRNA in the observation group(1.21±0.27)was significantly lower than that in the control group(1.57±0.37)(P<0.05).The median progression-free survival was significantly longer in the observation group(6.22 months[95%CI:5.63～6.63])than in the control group(3.66 months[95%CI:3.01～3.74])(P<0.05).The 3-year overall survival rate was 12.70%in the observation group,significantly higher than 0.00%in the control group(P<0.05).Conclusion:The combination of dexamethasone and abiraterone demonstrates significant efficacy in treating CRPC patients.It can markedly improve urodynamic parameters,downregulate HoxB13 expression in peripheral blood circulating tumor cells without significantly affecting AR-V7 expression,prolong progression-free survival,and increase the 3-year overall survival rate.关键词
去势抵抗性前列腺癌/人同源盒基因B13/地塞米松/雄激素受体剪切变异体7/阿比特龙/尿流动力学/生存预后Key words
castration-resistant prostate cancer(CRPC)/human homeobox B13(HoxB13)/dexamethasone/androgen receptor splice variant 7(AR-V7)/abiraterone/urodynamics/survival prognosis分类
医药卫生引用本文复制引用
张建龙,黄新化,吴钦福,易熠,林超禄..阿比特龙联合地塞米松治疗去势抵抗性前列腺癌患者的疗效及预后[J].中国肿瘤生物治疗杂志,2025,32(11):1175-1180,6.
